(Q54568691)

1 June 2018

title

Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. (English)

1 reference

1 June 2018

1 reference

Jiannan Wu

1

1 reference

1 June 2018

Shunrong Li

series ordinal

2

1 reference

1 June 2018

Weijuan Jia

series ordinal

3

1 reference

1 June 2018

Fengxi Su

series ordinal

4

1 reference

1 June 2018

publication date

10 August 2011

1 reference

1 June 2018

Journal of Cancer Research and Clinical Oncology

published in

1 reference

1 June 2018

volume

137

1 reference

1 June 2018

issue

10

1 reference

1 June 2018

page(s)

1505-1510

1 reference

1 June 2018

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1029-6

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1029-6

The role of BRCA1 in the cellular response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1029-6

Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1029-6

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1029-6

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1029-6

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1029-6

Prognostic markers in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1029-6

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1029-6

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1029-6

Targeting the DNA repair defect of BRCA tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1029-6

Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1029-6

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

12 December 2020

Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06

1 reference

12 December 2020

Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome

1 reference

12 December 2020

BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis

1 reference

12 December 2020

Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation

1 reference

12 December 2020

The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin

1 reference

12 December 2020

10.1007/S00432-011-1029-6

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018